December 1, 2025 — Algernon Health Inc. (CSE: AGN, FRANKFURT: AGW0, OTCQB: AGNPF) has announced the closing of the second tranche of its non-brokered private placement. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units at CAD $0.07 per unit. No cash finder’s fees were paid by the company.
Algernon previously announced the private placement on November 6, 2025, and closed the first tranche on November 14, 2025. The Canadian healthcare company plans to use the proceeds to advance its Alzheimer’s Disease (AD) program, including opening its first U.S. AD clinic. Funds will also cover general and administrative expenses and working capital needs.
The securities issued and issuable, as described in this release and the previous release on November 6, 2025, are subject to a statutory hold period of four months plus a day from the issuance date, in accordance with Canadian securities legislation.
The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” absent registration or an applicable exemption.
Christopher J. Moreau
CEO
Algernon Health Inc.
604.398.4175 Ext 701
cjmoreau@algernonhealth.com
Algernon Health is a Canadian healthcare company focused on brain-optimized PET scanning services through a planned network of new clinics in North America for early-stage detection of Alzheimer’s Disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA LLC, that will oversee all U.S. neuroimaging operations.
Neither the Canadian Securities Exchange nor its Market Regulator accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to planned brain-specific neuroimaging PET scanning clinic opening timelines, planned financings in the Company and its subsidiary and the closings of additional tranches thereof, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Source: Algernon Health
